Drug Delivery
11 Results were found on Technologies
Sub Category Name
Innovative Drug Delivery: Hydrogel-Forming Microneedles with Programmed Mesophase Transitions
An innovative drug delivery system utilizing hydrogel-forming microneedles that undergo programmed mesophase transitions. This technology allows for the controlled release of drugs, enhancing the efficacy and safety of pharmaceutical treatments. The microneedles transition from solid to swollen hydrogel upon contact with biological fluids, followed by further transformation into hydrogel microparticles, which facilitates a sustained release […] Read More >
Plant-Derived Anti- Herpesvirus Composition
Herpes simplex virus infection is commonly known as herpes. The two types of herpes simplex virus are HSV-1 (known to cause orofacial disease such as cold sores) and HSV-2 (causes genital infections). Over 80% of herpes infections is asymptomatic. Symptomatic infections are presented with blistering sores, pain during urination, swollen lymph nodes, and fever. Acyclovir […] Read More >
Novel Human Anti-Met Monoclonal Antibodies for Cancer Immunotherapy
MET is clinically validated target in several cancer types. MET operates just downstream to the famous P53. Addiction of cancers like breast and lung to MET as well as its absence from healthy adult tissues makes it a highly desirable target. Existing anti-MET marketed drugs (crizotinib & cabozantinib) are non-specific kinase inhibitors, having high toxicity […] Read More >
Targeting miR126-5p: A Novel RNA-Based Therapeutic Strategy for ALS
Amyotrophic Lateral Sclerosis (ALS) is a devastating and fatal neurodegenerative disease affecting motor neurons, leading to progressive paralysis. With a lifetime risk of 1:400 and no effective treatment available, there is an urgent need for novel therapeutic strategies to slow disease progression and improve patient outcomes. OUR SOLUTION We have identified miR126-5p as a novel […] Read More >
Repurposing of Antibiotics for treating APC (Adenomatous Polyposis Coli) Related Colorectal Cancer
Restoration of Adenomatous Polyposis Coli (APC) gene expression by means of antibiotic erythromycin for the treatment of Familial Adenomatous Polyposis. The Technology: Treatment for APC by conventional antibiotics to regulate adenoma growth and delay the need for preventive surgery in Familial Adenomatous Polyposis (FAP) patients. The Need: FAP is a high penetrance devastating syndrome manifested […] Read More >
Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer
Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >
SK4 K+ channel blockers: a new treatment for cardiac atrial fibrillation
We discovered a previously unidentified target in the heart, namely the SK4 calcium-activated K+ channels, which are functionally expressed in pacemaker cells as well as in atrial and ventricular cardiomyocytes. They are crucial for proper cardiac function and represent a completely new therapeutic target for the treatment of cardiac arrhythmias. SK4 channel blockers successfully prevented […] Read More >
An Oncolytic Virus That Exploits Immune Defects of Cancer Cells
An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy. Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEED On Nov. 2015 the FDA approved the first oncolytic virus based treatment. […] Read More >
Synthetic 9-cis beta Carotene for treatment of retinal degeneration
9-cis β-carotene-rich is an effective treatment for retinal diseases. Its production in algae was a bottleneck of clinical trials. Now there is a new a synthetic method for its production. BACKGROUNDAge related macular degeneration (AMD) and Retinitis pigmentosa (RP) are a leading cause of vision incapacitation and blindness worldwide (>30 million people). In recent clinical […] Read More >
Novel Specific Disease-Modifying PERK Activator for Huntington’s Disease
The need: There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. • Gene therapy-based clinical trials have failed so far, highlighting the need for other approaches. These include the recent interruption of antisense oligonucleotide clinical trials for HD. Background […] Read More >
